Authors
Israel Casanova-Méndez, Guillermo A Quintana-Mexiac, José L Alcalá-Gallegos, Henry Velazquez-Soto, Lorenzo Islas-Vázquez, Michelle Pacheco-Quito, Concepción Santacruz-Valdés, María C Jiménez-Martínez
Published in
Journal of clinical medicine. Volume 15. Issue 15. Jul 30, 2026. Epub Jul 30, 2026.
Abstract
Background/Objectives: Allergic conjunctivitis (AC) is a frequent inflammatory ocular surface disease that significantly affects quality of life, particularly in children. Current treatments mainly provide temporary symptom relief and often require prolonged use. Bacterial suspensions have emerged as potential immunomodulatory treatments for other allergies but have yet to be completely explored for ocular allergies. Our study's objective was to describe the clinical, ophthalmological, and quality-of-life changes in patients with AC treated with a bacterial suspension (BS) as complementary therapy. Methods: A before-and-after open, non-controlled clinical study was conducted in five children aged 7 to 9 years with a diagnosis of moderate-to-severe persistent allergic conjunctivitis and negative skin prick test results. Clinical ocular signs and symptoms, quality of life, and changes in CD19+IL-10+ cells were assessed. Results: After 90 days of BS treatment, reductions in allergic symptoms, including itching, light sensitivity, and burning, were observed, along with a marked reduction in ocular inflammation. An evaluation of quality-of-life revealed improvements across all domains and an increase in CD19+IL-10+ cells. Conclusions: BS therapy demonstrated favorable clinical and immune-modulatory effects in children with AC, supporting its potential as a promising complementary therapeutic option.
PMID:
42590065
Bibliographic data and abstract were imported from PubMed on 13 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0